VC-backed Abcodia raises £5.25m

The investment will support the launch of Abcodia's new ovarian cancer screening technology, Roca, which will begin testing in the UK and the US this year. 

The funding round was led by SEP and CIC, both of which join existing investors Albion and UCL Business.

Previous investment
Abcodia raised £1m from Albion and UCL Business in May 2011, with Albion investing £750,000 in that first round.

Company
London-based Abcodia has developed new ovarian cancer screening technology, Roca, which uses a data approach underpinned by a unique biobank that enhances the way biomarkers are developed, enabling earlier diagnosis.

In partnership with University College London, Abcodia focuses on developments in disease lifecycle, using the world's largest serum biobank and clinical database to evaluate potential tests for the early detection of disease.

The company formed an alliance with Cancer Research UK and Cancer Research Technology in 2013 to discover and validate blood-based biomarkers that can be used in cancer screening.

People
As part of the transaction, CIC's Robert Tansley and Jan Rutherford of SEP have joined Abcodia's board. Julie Barnes is CEO of Abcodia.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Early-stage
• Albion Ventures
• Scottish Equity Partners
• CIC